The present technology relates generally to implantable gastric devices. In particular, the present technology relates to inflation devices for implanting and inflating an intragastric device in situ and associated systems and methods.
Implantable gastric devices can occupy a volume within a patient's stomach to decrease the available room for food. This creates a feeling of satiety that can control the patient's appetite and cause weight loss. Intragastric balloons, for example, can be filled with a biocompatible fluid (e.g., saline solution) and left within the stomach for an extended period of time to treat obesity and/or other weight related conditions. Implanting such an intragastric balloon generally includes inserting the deflated balloon through the patient's mouth or nose with a filler tube or catheter, and inflating the balloon in situ. The intragastric balloon can eventually be removed by deflating the balloon, grasping it with an extraction tool, and removing the intragastric balloon via the esophagus and mouth.
A challenge associated with the inflation of intragastric balloons is that conventional inflation tools can inadvertently disconnect from the intragastric balloons during insertion and/or inflation. However, if it is difficult to disconnect the intragastric balloon from the inflation tools, the extra force (e.g., tugging) necessary for disengagement can agitate or impose trauma on the stomach wall. Thus, there is a need to improve the inflation of intragastric devices.
Specific details of several embodiments of the present technology are described below with reference to an inflation device for an intragastric device and associated methods for inflating, implanting, and explanting such devices. Although many of the embodiments are described below with respect to a dual balloon intragastric device, other embodiments of intragastric devices can include only one balloon or more than two balloons. Moreover, several further embodiments of the technology can have different configurations, components, or procedures than those described in this section. A person of ordinary skill in the art, therefore, will accordingly understand that the technology may have other embodiments with additional elements, or the technology may have other embodiments without several of the features shown and described below with reference to
The terms “distal” and “proximal” within this application reference a relative position of portions of an intragastric device and/or an inflation device with reference to an operator. Proximal refers to a position closer to the operator of the device, and distal refers to a position that is more distant from the operator of the device.
Each lumen 40 may have a corresponding inflation port 47 at a proximal end thereof. The inflation ports 47 may be configured to allow infusion of fluids into corresponding lumens 40 and inhibit or prevent the exit of fluids from the same. The inflation ports 47 may include check valves, clack valves, non-return valves, one-way valves, duckbill valves, reed valves, flapper valves, etc. For example, the first inflation port 47a may be provided at a proximal end of the first lumen 40a. Likewise, the second inflation port 47b may be provided at a proximal end of the second lumen 40b.
As shown in
Each balloon 30 may have an opening that fluidly connects the interior portion of the balloon 30 with at least a portion of the corresponding lumen 40. As shown in
As further shown in
Additionally, as shown in
The inner detent 304 may mate against a proximal portion of the proximal cap 200. Before, during, or after such mating, the first barb 320a may be inserted into the first inflation port 47a to provide fluid to the first lumen 40a, and the second barb 320b may be inserted into the second inflation port 47b to provide fluid to the second lumen 40b. In the embodiment illustrated in
As shown in
The open space 391 may provide a channel into which the proximal cap 200 may expand. For example, insertion of at least one of the barbs 320 into the corresponding inflation ports 47 may cause expansion of the proximal cap 200. At least some of the expansion of the proximal cap 200 may occur into the open space 391 rather than against the outer detent 302. The distribution of this expansion may increase the force required to disengage the outer detent 302 from the proximal cap 200, further allowing the proximal cap material to deflect when the barbs 320 are retracted. This allows a user to selectively reduce the engagement force of the outer 302 detent to the proximal cap 200.
In selected embodiments, engaging the intragastric device 10 with the inflation device 800 may be performed in situ within a gastric cavity of a patient. For example, the inflation device 800 may be attached to an intragastric device 10 that was previously deployed within the gastric cavity.
In other embodiments, engaging the intragastric device 10 with the inflation device 800 may be performed before insertion into a patient. For example, the intragastric device 10 and the inflation device 800 may be provided together in an engaged state or as a part of a kit of parts. Directions for use may further be provided. In the engaged state, the outer detent 302 may be mated around to a distal portion of the proximal cap 200, the inner detent 304 may be mated against a proximal portion of the proximal cap 200, and the first barb 320a and the second barb 320b may be mated within the first inflation port 47a and the second inflation port 47b, respectively. In the engaged state, the proximal cap 200 may be expanded.
The engaged intragastric device 10 and the inflation device 800 may be delivered to a gastric cavity. A fluid may be flowed to intragastric device 10. For example, the fluid may flow through at least one of the first handle 330a, the first tube 310a, the first barb 320a, the first inflation port 47a, the first inflation chamber 42a, the first inflation opening 32a, and the first balloon 30a. Similarly, the fluid may flow through at least one of the second handle 330b, the second tube 310b, the second barb 320b, the second inflation port 47b, the second inflation chamber 43b, the second inflation opening 33b, and the second balloon 30b. As such, at least one of the first balloon 30a and the second balloon 30b may be inflated to a desired volume.
In selected embodiments, the first balloon 30a and the second balloon 30b may be inflated simultaneously. Similarly, any number of balloons 30 may be inflated simultaneously corresponding to the number of separate inflation structures (e.g., handles 330, tubes 310, barbs 340, inflation ports 47, inflation chambers 42, and inflation openings 32). A plurality of inflation structures may reduce the total amount of time required to inflate the balloons 30 of intragastric device 10 by a factor corresponding to the number of inflation structures. For example, where N number of inflation structures are provided, the amount of time required to inflate the balloons 30 of the intragastric device 10 may be reduced by a factor of N. Additionally, because each balloon 30 includes at least one corresponding inflation structure, there is no need to attach a barb 320 to one inflation port 47, inflate, detach, and repeat the process with another inflation port 47.
As shown in
To disengage and separate the inflation device 800 from the intragastric device, the outer detent 302 may be removed from around the proximal cap 200 and the inner detent 304 may be removed from against the proximal cap 200. In selected embodiments, such separation of the inflation device 800 from the intragastric device 10 can result from the application of lateral forces. For example, the inflation device 800 may be advanced against the inflated gastric device 10, causing it to distort or rotate. The distorted shape or rotation of intragastric device 10 may cause a lateral force to be applied at the engagement location of the intragastric device 10 and the inflation device 800, causing it to buckle at the engagement location. Such forces may exceed the forces maintaining engagement. As described above, the forces maintaining engagement can be reduced after removal of the first barb 320a and/or the second barb 320b or by the mating interface 390. The reduction of this force may likewise reduce the force placed on the gastric wall supporting such actions. The body of the inflation device 800 may provide an opposing force to retract the barbs 320 such that the inserted barbs 320 do not exceed engagement forces, but with the removed barbs 320 it does exceed engagement forces. This allows for secure placement as well as very little to no pull force on removal of the inflation device 800.
In other embodiments, the inflation device 800 may be separated from the intragastric device 10 by opposing forces. A tension force may be provided by retracting the inflation device 800 at a second end thereof. An opposing force against the intragastric device 10 may be provided by the gastroesophageal junction. The junction may provide such a force after the balloon(s) 30 of intragastric device 10 are inflated such that a diameter thereof exceeds the diameter of the gastroesophageal junction. When force is applied from the gastroesophageal junction, it is inherent that a substantially equal tensile force applies to the engagement location of the inflation device 800. Reduction of the force required to disengage inflation device 800 from intragastric device 10 may be beneficial in that the force applied to and from the gastroesophageal junction is reduced. Accordingly, trauma to the gastroesophageal junction is likewise reduced.
In further embodiments, a force may be applied to the intragastric device 10 from another device that holds the intragastric device 10 in place relative to the retraction of the inflation device 800. For example, a rigid or partially rigid structure may hold the intragastric device 10 in place while the inflation device 800 is retracted.
As further shown in
Additionally, the inflation assembly 1300, the inflation devices 300 and 800, and/or the intragastric device 10 described above can include features that reduce or prevent the mitigation of bacteria into the intragastric device 10 during or after implantation, inflation, deflation, and/or removal procedures. For example, the inflation assembly 1300 and the intragastric device 10 can include features that prevent bacteria from entering the balloons 30, and/or prevent bacteria from growing inside the balloons 30 during and after implantation. These features can prevent detrimental expansion of the balloons 30 caused by bacterial growth and its by-products (e.g., gas), reduce the likelihood of infection, and/or otherwise decrease failure of the intragastric device 10.
In selected embodiments, for example, components of the intragastric device 10, the inflation devices 300 and 800, the inflation assembly 1300, and/or associated devices (e.g., the delivery catheter, secondary inflation lines, syringes, containers, etc.) can be sterilized. The individual components of the inflation assembly 1300, the intragastric device 10, and/or other related tools and devices may be stored within a sterile kit as individual sterilized components. A sterile area or field can be used for set-up, implantation, and/or removal of the intragastric device 10. For example, associated devices can be attached to the inflation devices 300 and 800 on a sterile device tray, card, and/or other sterile working space before implantation. This sterile field can be packaged with the inflation devices 300 and 800, intragastric device 10, and/or inflation assembly 1300. Additionally, a cover (e.g., a hood, a cap) can encase connection sites (e.g., lures), the handles 330, related injection lines, fluid insertion containers 1304, and/or other components before implantation of the intragastric device 10. These covers can maintain the sanitation of the inflation devices 300 and 800, intragastric device 10, the inflation assembly 1300, and/or associated devices during implantation and inflation procedures. For example, covers can be pre-attached to portions (e.g., connection sites) of the inflation devices 300 and 800, intragastric device 10, and/or the inflation assembly 1300, such that the covered portion remains sanitized.
In other embodiments, the intragastric device 10, the inflation devices 300 and 800, the inflation assembly 1300, and/or portions thereof can be pre-attached before implantation such that the joined components can be sterilized together. For example, the inflation assembly 1300 can be pre-attached to the tubes 310. As another example, the inflation devices 300 and 800 can be pre-attached to the intragastric device 10.
In further embodiments, the inflation devices 300 and 800, the intragastric device 10, and/or associated devices can be comprised at least partially of materials with anti-microbial agents or other anti-bacterial features. The balloons 30, for example, can be made from a diphenyl loaded material. Additionally, the balloons 30 can be pressurized to reduce bacteria ingress.
The balloons 30 can also be filled with bacteriostatic fillants to prevent bacteria from growing within the balloons 30. For example, a sterile 0.9% sodium chloride solution bacteriostatic may be used as a fillant. Bacteriostatic agents can also be incorporated directly into the fillant. In selected embodiments, a bacteriostatic sealant, such as mineral oil with preservatives (e.g., tacophenol) can be used to kill expected bio-burden within the balloons 30.
In further embodiments, the inflation devices 300 and 800, the intragastric device 10, and/or other associated delivery and inflation devices can include other features to limit bacterial growth within the balloons 30. In selected embodiments, bacterial food sources can be reduced or eliminated. For example, powdered food sources (e.g. corn starch) on the intragastric device 10 and/or the inflation devices 300 and 800 may be replaced with sodium bicarbonate that is a less accessible carbon food source and creates a pH environment that is not favorable for some intragastric microbes. In other embodiments, a surface treatment (e.g., silicone dispersion) may be applied to interior portions of the balloons 30 to fill open pores in the balloon material. Lubricants (e.g., mineral oil) can also be injected inside the balloons 30 to fill porous portions. Inert and/or bacteriostatic dusting powder (e.g., zinc oxide, amoxicillin, barium sulfate, etc) can also be used within or over the balloons 30.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the technology. For example, the intragastric device 10 shown in
The present application is a U.S. National Phase application under 35 U.S.C. 371 of International Application Serial No. PCT/US2011/031463, filed Apr. 6, 2011, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/321,466, filed Apr. 6, 2010, the entire contents of which are incorporated herein by reference in their entireties. This application incorporates by reference in their entirety each of the following applications and publications: U.S. patent application Ser. No. 11/768,152, filed Jun. 25, 2007, entitled GASTRIC SPACE FILLER DEVICE, DELIVERY SYSTEM, AND RELATED METHODS; U.S. patent application Ser. No. 11/263,302, filed Oct. 31, 2005, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0100367, published May 3, 2007, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0100368, published May 3, 2007, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0100369, published May 3, 2007, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0149994, published Jun. 28, 2007, entitled INTRAGASTRIC SPACE FILLER AND METHODS OF MANUFACTURE; U.S. Pat. Pub. No. 2008/0243071, published Oct. 2, 2008, entitled INTRAGASTRIC BALLOON SYSTEM AND THERAPEUTIC PROCESSES AND PRODUCTS; U.S. Pat. Pub. No. 2008/0319471, published Dec. 25, 2008, entitled GASTRIC SPACE FILLER DEVICE, DELIVERY SYSTEM, AND RELATED METHODS; U.S. Pat. Pub. No. 2005/0159769, published Jul. 21, 2005, entitled BALLOON SYSTEM AND METHODS FOR TREATING OBESITY; U.S. Pat. Pub. No. 2009/0048624, published Feb. 19, 2009, entitled BALLOON SYSTEM AND METHODS FOR TREATING OBESITY; WIPO Pub. No. WO 2007/053556, published Oct. 5, 2007, entitled INTRAGASTRIC SPACE FILLER; WIPO Pub. No. WO 2007/053707, published Oct. 5, 2007, entitled INTRAGASTRIC SPACE FILLER; WIPO Pub. No. WO 2007/053706, published Oct. 5, 2007, entitled INTRAGASTRIC SPACE FILLER; and WIPO Pub. No. WO 2007/075810, published May 7, 2007, entitled INTRAGASTRIC SPACE FILLER.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2011/031463 | 4/6/2011 | WO | 00 | 2/4/2013 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2011/127205 | 10/13/2011 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
1666690 | Drevitson | Apr 1928 | A |
1690995 | Pratt | Nov 1928 | A |
2493326 | Trinder | Jan 1950 | A |
2579301 | Buntin | Dec 1951 | A |
3131867 | Miller et al. | May 1964 | A |
4133315 | Berman et al. | Jan 1979 | A |
4198983 | Becker et al. | Apr 1980 | A |
4246893 | Berson | Jan 1981 | A |
4281582 | Jaqua | Aug 1981 | A |
4356824 | Vazquez | Nov 1982 | A |
4368739 | Nelson, Jr. | Jan 1983 | A |
4416267 | Garren et al. | Nov 1983 | A |
4436087 | Ouchi et al. | Mar 1984 | A |
4465072 | Taheri | Aug 1984 | A |
4465818 | Shirahata et al. | Aug 1984 | A |
4485805 | Foster, Jr. | Dec 1984 | A |
4543089 | Moss | Sep 1985 | A |
4598699 | Garren et al. | Jul 1986 | A |
4694827 | Weiner et al. | Sep 1987 | A |
4723547 | Kullas et al. | Feb 1988 | A |
4899747 | Garren et al. | Feb 1990 | A |
4940458 | Cohn | Jul 1990 | A |
5073347 | Garren et al. | Dec 1991 | A |
5084061 | Gau et al. | Jan 1992 | A |
5123840 | Nates | Jun 1992 | A |
5234454 | Bangs | Aug 1993 | A |
5259399 | Brown | Nov 1993 | A |
5263934 | Haak | Nov 1993 | A |
5273536 | Savas | Dec 1993 | A |
5318530 | Nelson, Jr. | Jun 1994 | A |
5334187 | Fischell et al. | Aug 1994 | A |
5431173 | Chin et al. | Jul 1995 | A |
5496271 | Burton et al. | Mar 1996 | A |
5516812 | Chu et al. | May 1996 | A |
5575772 | Lennox | Nov 1996 | A |
5639810 | Smith, III et al. | Jun 1997 | A |
5643209 | Fugoso et al. | Jul 1997 | A |
5730722 | Wilk | Mar 1998 | A |
5779728 | Lunsford et al. | Jul 1998 | A |
5857991 | Grothoff et al. | Jan 1999 | A |
5876376 | Schwab et al. | Mar 1999 | A |
5904701 | Daneshvar | May 1999 | A |
5938669 | Klaiber et al. | Aug 1999 | A |
5976073 | Ouchi | Nov 1999 | A |
5993473 | Chan et al. | Nov 1999 | A |
5997503 | Willis et al. | Dec 1999 | A |
6149621 | Makihara | Nov 2000 | A |
6179878 | Duerig et al. | Jan 2001 | B1 |
6254355 | Gharib | Jul 2001 | B1 |
6276567 | Diaz et al. | Aug 2001 | B1 |
6280411 | Lennox | Aug 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6427089 | Knowlton | Jul 2002 | B1 |
6454785 | De Hoyos Garza | Sep 2002 | B2 |
6524234 | Ouchi | Feb 2003 | B2 |
6535764 | Imran et al. | Mar 2003 | B2 |
6540789 | Silverman et al. | Apr 2003 | B1 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6579301 | Bales et al. | Jun 2003 | B1 |
6592552 | Schmidt | Jul 2003 | B1 |
6613018 | Bagga et al. | Sep 2003 | B2 |
6613037 | Khosravi et al. | Sep 2003 | B2 |
6689051 | Nakada | Feb 2004 | B2 |
6706010 | Miki et al. | Mar 2004 | B1 |
6746460 | Gannoe et al. | Jun 2004 | B2 |
6826428 | Chen et al. | Nov 2004 | B1 |
6850128 | Park | Feb 2005 | B2 |
6866627 | Nozue et al. | Mar 2005 | B2 |
6866657 | Shchervinsky | Mar 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6890300 | Lloyd et al. | May 2005 | B2 |
6890346 | Ganz et al. | May 2005 | B2 |
6902535 | Eberhart et al. | Jun 2005 | B2 |
6923754 | Lubock | Aug 2005 | B2 |
6931286 | Sigg et al. | Aug 2005 | B2 |
6939299 | Petersen et al. | Sep 2005 | B1 |
6942680 | Grayzel et al. | Sep 2005 | B2 |
6958052 | Charlton | Oct 2005 | B1 |
7001419 | DiCaprio et al. | Feb 2006 | B2 |
7016735 | Imran et al. | Mar 2006 | B2 |
7020531 | Colliou et al. | Mar 2006 | B1 |
7033373 | de la Torre et al. | Apr 2006 | B2 |
7056305 | Garza Alvarez | Jun 2006 | B2 |
7076305 | Imran et al. | Jul 2006 | B2 |
7081125 | Edwards et al. | Jul 2006 | B2 |
7131945 | Fink et al. | Nov 2006 | B2 |
7483746 | Lee et al. | Jan 2009 | B2 |
7625355 | Yu | Dec 2009 | B2 |
7749254 | Sobelman et al. | Jul 2010 | B2 |
7828749 | Douglas et al. | Nov 2010 | B2 |
7829572 | Didiuk et al. | Nov 2010 | B2 |
7931693 | Binmoeller et al. | Apr 2011 | B2 |
8083757 | Gannoe et al. | Dec 2011 | B2 |
8556925 | Makower et al. | Oct 2013 | B2 |
8840952 | Ashby et al. | Sep 2014 | B2 |
8894568 | Pecor et al. | Nov 2014 | B2 |
9050174 | Pecor et al. | Jun 2015 | B2 |
9149611 | Bouasaysy | Oct 2015 | B2 |
20010022988 | Schwarz et al. | Sep 2001 | A1 |
20010037127 | De Hoyos Garza | Nov 2001 | A1 |
20020055757 | Torre et al. | May 2002 | A1 |
20020107515 | Edwards et al. | Aug 2002 | A1 |
20020161388 | Samuels et al. | Oct 2002 | A1 |
20020173804 | Rousseau | Nov 2002 | A1 |
20030105800 | Cullen | Jun 2003 | A1 |
20030114878 | Diederich et al. | Jun 2003 | A1 |
20030171768 | McGhan | Sep 2003 | A1 |
20030187390 | Bates et al. | Oct 2003 | A1 |
20040044354 | Gannoe et al. | Mar 2004 | A1 |
20040059289 | Garza Alvarez | Mar 2004 | A1 |
20040059290 | Palasis | Mar 2004 | A1 |
20040073162 | Bleam et al. | Apr 2004 | A1 |
20040087902 | Richter | May 2004 | A1 |
20040093058 | Cottone et al. | May 2004 | A1 |
20040106899 | McMichael et al. | Jun 2004 | A1 |
20040116897 | Aboul- Hosn | Jun 2004 | A1 |
20040127915 | Fleenor et al. | Jul 2004 | A1 |
20040186502 | Sampson et al. | Sep 2004 | A1 |
20040186503 | DeLegge | Sep 2004 | A1 |
20040220665 | Hossainy et al. | Nov 2004 | A1 |
20040236280 | Rice et al. | Nov 2004 | A1 |
20040236361 | Sakurai | Nov 2004 | A1 |
20040254600 | Zarbatany et al. | Dec 2004 | A1 |
20050027283 | Richard et al. | Feb 2005 | A1 |
20050027313 | Shaker | Feb 2005 | A1 |
20050038415 | Rohr et al. | Feb 2005 | A1 |
20050055039 | Burnett et al. | Mar 2005 | A1 |
20050059990 | Ayala et al. | Mar 2005 | A1 |
20050075624 | Miesel | Apr 2005 | A1 |
20050085792 | Gershowitz | Apr 2005 | A1 |
20050119674 | Gingras | Jun 2005 | A1 |
20050131442 | Yachia et al. | Jun 2005 | A1 |
20050143784 | Imran | Jun 2005 | A1 |
20050159769 | Alverdy | Jul 2005 | A1 |
20050177103 | Hunter et al. | Aug 2005 | A1 |
20050192614 | Binmoeller | Sep 2005 | A1 |
20050192615 | Torre et al. | Sep 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050267595 | Chen et al. | Dec 2005 | A1 |
20050267596 | Chen et al. | Dec 2005 | A1 |
20050273060 | Levy et al. | Dec 2005 | A1 |
20060058829 | Sampson et al. | Mar 2006 | A1 |
20060142700 | Sobelman et al. | Jun 2006 | A1 |
20060178691 | Binmoeller | Aug 2006 | A1 |
20060184112 | Horn et al. | Aug 2006 | A1 |
20060259020 | Sharratt | Nov 2006 | A1 |
20060270906 | Matsuno et al. | Nov 2006 | A1 |
20070016262 | Gross et al. | Jan 2007 | A1 |
20070078476 | Hull et al. | Apr 2007 | A1 |
20070083224 | Hively | Apr 2007 | A1 |
20070093728 | Douglas et al. | Apr 2007 | A1 |
20070100367 | Quijano et al. | May 2007 | A1 |
20070100368 | Quijano et al. | May 2007 | A1 |
20070100369 | Cragg et al. | May 2007 | A1 |
20070118168 | Lointier et al. | May 2007 | A1 |
20070135829 | Paganon et al. | Jun 2007 | A1 |
20070142770 | Rioux et al. | Jun 2007 | A1 |
20070149994 | Sosnowski et al. | Jun 2007 | A1 |
20070173881 | Birk et al. | Jul 2007 | A1 |
20070233161 | Weller et al. | Oct 2007 | A1 |
20070250020 | Kim et al. | Oct 2007 | A1 |
20070265369 | Muratoglu et al. | Nov 2007 | A1 |
20070265598 | Karasik | Nov 2007 | A1 |
20070288033 | Murature et al. | Dec 2007 | A1 |
20080058887 | Griffin et al. | Mar 2008 | A1 |
20080082056 | Mauch et al. | Apr 2008 | A1 |
20080085887 | Didiuk et al. | Apr 2008 | A1 |
20080097513 | Kaji et al. | Apr 2008 | A1 |
20080119729 | Copa et al. | May 2008 | A1 |
20080172079 | Birk | Jul 2008 | A1 |
20080190363 | Chen et al. | Aug 2008 | A1 |
20080208135 | Annunziata et al. | Aug 2008 | A1 |
20080208241 | Weiner et al. | Aug 2008 | A1 |
20080233167 | Li et al. | Sep 2008 | A1 |
20080243071 | Quijano et al. | Oct 2008 | A1 |
20080243166 | Paganon et al. | Oct 2008 | A1 |
20080255601 | Birk | Oct 2008 | A1 |
20080312679 | Hardert et al. | Dec 2008 | A1 |
20080319471 | Sosnowski et al. | Dec 2008 | A1 |
20090048624 | Alverdy | Feb 2009 | A1 |
20090250236 | Burnett et al. | Oct 2009 | A1 |
20090275973 | Chen et al. | Nov 2009 | A1 |
20090287231 | Brooks et al. | Nov 2009 | A1 |
20100023047 | Simpson | Jan 2010 | A1 |
20100049224 | Vargas | Feb 2010 | A1 |
20100063530 | Valencon et al. | Mar 2010 | A1 |
20100130998 | Alverdy | May 2010 | A1 |
20100174307 | Birk | Jul 2010 | A1 |
20100191270 | Garza et al. | Jul 2010 | A1 |
20100234853 | Pecor et al. | Sep 2010 | A1 |
20100243135 | Pepper et al. | Sep 2010 | A1 |
20100251837 | Bouasaysy et al. | Oct 2010 | A1 |
20110172767 | Rathi et al. | Jul 2011 | A1 |
20110178544 | Sosnowski et al. | Jul 2011 | A1 |
20110276076 | Paganon | Nov 2011 | A1 |
20110295300 | Verd et al. | Dec 2011 | A1 |
20120191126 | Pecor et al. | Jul 2012 | A1 |
20120271336 | Hamman et al. | Oct 2012 | A1 |
20120271338 | Bouasaysy et al. | Oct 2012 | A1 |
20120289992 | Quijano et al. | Nov 2012 | A1 |
20130035710 | Bouasaysy et al. | Feb 2013 | A1 |
20130053880 | Bouasaysy et al. | Feb 2013 | A1 |
20130102876 | Limon et al. | Apr 2013 | A1 |
20130261654 | Bouasaysy et al. | Oct 2013 | A1 |
20130296914 | Quijano et al. | Nov 2013 | A1 |
20140257358 | Alverdy et al. | Sep 2014 | A1 |
20140371775 | Ashby et al. | Dec 2014 | A1 |
20150216529 | Kwok et al. | Aug 2015 | A1 |
20150238342 | Sosnowski et al. | Aug 2015 | A1 |
20150265811 | Pecor et al. | Sep 2015 | A1 |
20150366691 | Bouasaysy et al. | Dec 2015 | A1 |
20160008156 | Pecor et al. | Jan 2016 | A1 |
Number | Date | Country |
---|---|---|
2638988 | May 2007 | CA |
8708978 | Nov 1987 | DE |
0103481 | Mar 1984 | EP |
0457456 | Nov 1991 | EP |
0485903 | May 1992 | EP |
1781183 | May 2007 | EP |
2862525 | May 2005 | FR |
2892297 | Apr 2007 | FR |
2090747 | Jul 1982 | GB |
2139902 | Nov 1984 | GB |
S57168674 | Oct 1982 | JP |
S6415063 | Jan 1989 | JP |
H091872 | Apr 1989 | JP |
H08322943 | Dec 1996 | JP |
2001128985 | May 2001 | JP |
2006333888 | Dec 2006 | JP |
2009285135 | Dec 2009 | JP |
2015154964 | Aug 2015 | JP |
2016127954 | Jul 2016 | JP |
8805671 | Aug 1988 | WO |
9000369 | Jan 1990 | WO |
9925418 | May 1999 | WO |
WO-0141700 | Jun 2001 | WO |
WO-0166166 | Sep 2001 | WO |
WO-0240081 | May 2002 | WO |
2005082296 | Sep 2005 | WO |
2005107641 | Nov 2005 | WO |
2005120363 | Dec 2005 | WO |
WO-2006035446 | Apr 2006 | WO |
WO-2006056944 | Jun 2006 | WO |
WO-2006128978 | Dec 2006 | WO |
WO-2007027812 | Mar 2007 | WO |
WO-2007053556 | May 2007 | WO |
WO-2007053706 | May 2007 | WO |
WO-2007053707 | May 2007 | WO |
WO-2007075810 | Jul 2007 | WO |
WO-2008042819 | Apr 2008 | WO |
WO-2008121831 | Oct 2008 | WO |
WO-2009055386 | Apr 2009 | WO |
WO-2009112786 | Sep 2009 | WO |
WO-2010048021 | Apr 2010 | WO |
WO-2010115161 | Oct 2010 | WO |
WO-2011011629 | Jan 2011 | WO |
WO-2011011741 | Jan 2011 | WO |
WO-2011011743 | Jan 2011 | WO |
WO-2011024077 | Mar 2011 | WO |
WO-2011038270 | Mar 2011 | WO |
WO-2011097637 | Aug 2011 | WO |
WO-2011127205 | Oct 2011 | WO |
WO-2012048226 | Apr 2012 | WO |
Entry |
---|
European Search Report—Supplementary; EP 03726447.0, Applicant: Applied Medical Resources Corporation: Mar. 1, 2006, 3 pgs. |
Final Office Action; U.S. Appl. No. 11/694,536, Mailing Date Mar. 11, 2011, 13 pages. |
Final Office Action; U.S. Appl. No. 11/768,152, Mailing Date Jan. 19, 2011, 13 pages. |
International Search Report; International Application No. PCT/US2010/042948; Applicant: ReShape Medical, Inc., Mailing Date Apr. 1, 2011, 11 pages. |
International Search Report; International Application No. PCT/US2010/043134; Applicant: ReShape Medical, Inc., Mailing Date Apr. 27, 2011, 12 pages. |
International Search Report; International Application No. PCT/US2010/043136; Applicant: ReShape Medical, Inc., Mailing Date Apr. 12, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2010/050260; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 17, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2011/026233; Applicant: ReShape Medical, Inc., Mailing Date Apr. 26, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2011/031463; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 27, 2011, 10 pages. |
International Search Report; International Application No. PCT/US2003/012782, Applicant: Applied Medical Resources Corporation, dated: Oct. 28, 2003, 7 pages. |
International Search Report; International Application No. PCT/US2006/042336, Applicant: Abdominus, Inc., dated: Mar. 14, 2007, 9 pages. |
International Search Report; International Application No. PCT/US2006/042710, Applicant: Abdominus, Inc. et al., dated: Mar. 15, 2007, 9 pages. |
International Search Report; International Application No. PCT/US2006/042711, Applicant: Abdominus, Inc. et al, dated: Mar. 16, 2007, 9 pages. |
International Search Report; International Application No. PCT/US2006/048647, Applicant: Abdominus, Inc. et al., dated: May 22, 2007, 12 pages. |
International Search Report; International Application No. PCT/US2008/058677, Applicant: ReShape Medical et al., dated: Aug. 21, 2008, 12 pages. |
International Search Report; International Application No. PCT/US2008/068058, Applicant: ReShape Medical, Inc. et al, dated: Nov. 19, 2008, 11 pages. |
International Searbh Report; International Application No. PCT/US2010/029865, Applicant: ReShape Medical, Inc., dated: Jan. 5, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2011/024077; Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 12 pages. |
International Search Report; International Application No. PCT/US2011/024082, Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 10 pages. |
International Search Report; International Application No. PCT/US1155373, Applicant: Reshape Medical, Inc., dated: Jan. 20, 2012, 7 pages. |
“Living with the BIB: BioEnterics Intragastric Balloon Program: Patient Information”; INAMED Health: Bioenteris Corporation, ECO-SBA-10434; dated Apr. 20, 2004 and May 14, 2005, located online at: www.sydneyobesity.com.au/pdf/M946-01.pdf; 10 pages. |
Non-Final Office Action; U.S. Appl. No. 11/263,302; dated: Oct. 9, 2012, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 11/694,536; dated: Oct. 26, 2011, 13 pages. |
Non-Final Office Action; U.S. Appl. No. 12/723,545; dated Feb. 29, 2012, 10 pages. |
Non-Final Office Action; U.S. Appl. No. 12/625,473; dated Oct. 24, 2011, 18 pages. |
Non-Final Office Action; U.S. Appl. No. 12/625,473; dated Jul. 12, 2012; 10 pages. |
Non-Final Office Action; U.S. Appl. No. 12/753,751; dated Oct. 5, 2012, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 13/074,956; dated Oct. 1, 2012, 8pages. |
ReShape Inflatable Gastric Balloon Going on Trial as Weight Loss Option, MedGadget: Internet Journal of Emerging Medical Technologies. Feb. 4, 2010, 5 pages. |
Wahlen CH et al. “The BioEnterics Intragastric Balloon: How to use it” Obesity Surgery 2001; 11:524-527. |
Extended European Search Report; Application No. EP11748141.6, Applicant: Reshape Medical, Inc., mailed Feb. 25, 2014, 6 pages. |
Final Office Action; U.S. Appl. No. 13/858,767, Mailing Date May 22, 2103, 12 pages. |
Extended European Search Report; Application EP11740536.5, Applicant: ReShape Medical, Inc., mailed Jul. 3, 2014, 8 pages. |
Extended European Search Report; Application EP11831683.5, Applicant: Reshape Medical, Inc., mailed Jul. 3, 2014, 8 pages. |
Final Office Action; U.S. Appl. No. 13/556,8-32, mailed on Jan. 28, 2014, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 13/386,650; mailed on Jun. 3, 2014, 15 pages. |
Notice of Allowance; U.S. Appl. No. 12/753,803, dated May 13, 2014, 18 pages. |
Ostrovsky, ReShape Inflatable Gastric Balloon going on Trial as Weight Loss Option; http://www.medgadget.com/2010/02/reshape—inflatable—gastric—balloon—system—going—on—trial—as—wieight—loss—option.html Feb. 4, 2010, retrieved on Feb. 10-2-13. |
European Supplementary Search Report; EP Application No. 10802994.3, Applicant: ReShape Medical, Inc., mailed Jun. 28, 2013, 8 pgs. |
European Supplementary Search Report; EP Application No. 10802918.2, Applicant: ReShape Medical, Inc., mailed Jun. 5, 2013, 6 pgs. |
Extended European Search Report; Application No. EP6827098.3, Applicant: Reshape Medical, Corporation, mailed on Aug. 25, 2014, 3 pages. |
Extended European Search Report; Application No. EP6827314.3, Applicant: ReShape Medical Corporation, mailed on Aug. 1, 2014, 3 pages. |
Extended European Search Report; Application No. EP6827313.5, Applicant: ReShape Medical Corporation, mailed on Jul. 30, 2014, 5 pages. |
Extended European Search Report; Application No. EP6847847.8, Applicant: ReShape Medical Corporation, mailed on Aug. 14, 2014, 5 pages. |
Final Office Action; U.S. Appl. No. 13/858,767, mailed on May 30, 2014, 12 pages. |
Non-Final Office Action; U.S. Appl. No. 13/386,638, mailed on Jun. 27, 2014, 12 pages. |
Extended European Search Report; Application No. EP11766679.2, Applicant Reshape Medical, Inc., mailed Dec. 12, 2013, 6 pages. |
Cronin, Carmel G. et al., “Normal small bowel wall characteristics on MR enterography,” European Journal of Radiology 74(2):207-211, Aug. 2010. |
Gray, Henry, Anatomy of the Human Body. Philadelphia: Lea & Febiger, 1918. Section XI Splanchnology, 2g. The Small Intestine. Bartleby.com, 2000. Web. URL: www.bartleby.com/107/248.html. Accessed: Oct. 26, 2015. 12 pages. |
Partial Supplementary European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Oct. 20, 2015, 7 pages. |
Final Office Action for Japanese Application No. 2014-52972, Applicant: ReShape Medical, Inc., mailed on Oct. 9, 2015, 8 pages. |
Canadian Office Action; Application No. CA 2638163, Applicant: Reshape Medical, Inc., mailed Dec. 8, 2015, 4 pages. |
Canadian 2nd Office Action Application No. 2680124, Applicant: ReShape Medical, Inc., mailed Jul. 9, 2015, 3 pages. |
European Examination Report; Application No. 06827313.5, Applicant: ReShape Medical Inc., mailed Jul. 13, 2015, 5 pages. |
European Examination Report; Application No. 06847847.8, Applicant: ReShape Medical Inc., mailed Jul. 13, 2015, 4 pages. |
Japanese Office Action; Application No. 2013-532976; Applicant: ReShape Medical, Inc., mailed Jun. 26, 2015, 10 pages. |
Canadian Office Action: Application No. CA 2680124, Applicant: Reshape Medical Corporation, mailed Nov. 4, 2014, 3 pages. |
Canadian Office Action; Application No. 2,691,530, mailed Dec. 18, 2014, 4 pages. |
Canadian Office Action; Application No. CA 2638163, Applicant: Reshape Medical Corporation, mailed Mar. 10, 2015, 4 pages. |
Canadian Office Action; Application No. CA 2638988, Applicant Reshape Medical Corporation, mailed Dec. 22, 2014 3 pages. |
Canadian Office Action; Application No. CA 2638988, Applicant Reshape Medical Corporation, mailed Mar. 6, 2014, 4 pages. |
Canadian Office Action; Application No. CA 2638989, Applicant: Reshape Medical Corporation, mailed May 22, 2013 3 pages. |
Canadian Office Action; Application No. CA 2640554, Applicant: Reshape Medical Corporation, mailed May 27, 2013, 2 pages. |
Canadian Office Action; Application No. CA2484838, Applicant: Reshape Medical, Inc., mailed Nov. 13, 2009, 3 pages. |
Canadian Office Action; Application No. CA2484838, Applicant: Reshape Medical, Inc., mailed Sep. 24, 2010, 3 pages. |
Canadian Office Action; Application No. CA2638163, Applicant: Reshape Medical Corporation, mailed Jul. 17, 2013, 2 pages. |
Canadian Office Action; Application No. CA2638988, Applicant: Reshape Medical Corporation, mailed May 28, 2013, 3 pages. |
Canadian Office Action; Application No. CA2780085, Applicant: Reshape Medical, Inc., mailed Jul. 23, 2012, 2 pages. |
European Examination Report; Application No. 03726447.0, Applicant: Applied Medical Resources Corporation: Oct. 26, 2007, 4 pages. |
European Examination Report; Application No. EP108002918.2, Applicant: Reshape Medical Inc., mailed Dec. 17, 2014, 5 pages. |
European Examination Report; Application No. EP108029943, Applicant: Reshape Medical Inc., mailed Dec. 18, 2014, 4 pages. |
European Examination Reported; Application No. 08771842.5, May 7, 2015, 5 pages. |
European Supplementary Search Report; Application No. 08771842.5, Apr. 24, 2015, 3 pages. |
Extended European Search Report; Application No. 08732989.2, Applicant: Reshape Medical, Inc., mailed Oct. 16, 2014, 7 pages. |
Japanese Final Office Action; Application No. JP2013-043712, mailed Nov. 15, 2013, 5 pages. |
Japanese Office Action; Application No. 2013-142327, mailed May 29, 2014, 4 pages. |
Japanese Office Action; Application No. 2014-52972; mailed Feb. 25, 2015, 7 pages. |
Japanese Office Action; Application No. JP2010-501261, mailed Sep. 7, 2012, 10 pages. |
Japanese Office Action; Application No. JP2010-515040, mailed Jan. 7, 2013, 18 pages. |
Japanese Office Action; Application No. JP2012-503759, mailed Mar. 24, 2014, 5 pages. |
Japanese Office Action; Application No. JP2013-43712, mailed Jan. 8, 2015, 8 pages. |
Japanese Office Action; Application. No. JP2013-043712, mailed Apr. 22, 2013, 5 pages. |
Chou, Chyuan et al., “Structural Effects On The Thermal Properties Of PDPS/PDMS Copolymers,” Journal of Thermal Analysis, vol. 40, pp. 657-667, 1993. |
European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Mar. 8, 2016, 14 pages. |
Extended European Search Report; Application No. 15198773.2, Application ReShape Medical Corporation, mailed Jul. 15, 2016, 7 pages. |
European Examination Report; Application No. 11766679.2, Applicant: Reshape Medical Inc., mailed Dec. 1, 2016, 4 pages. |
European Examination Report; Application No. 11748141.6, Applicant: Reshape Medical Inc., mailed Dec. 8, 2016, 3 pages. |
Extended European Search Report; Application No. 16183882.6, Applicant: Reshape Medical Inc., mailed Feb. 17, 2017, 9 pages. |
Number | Date | Country | |
---|---|---|---|
20140031850 A1 | Jan 2014 | US |
Number | Date | Country | |
---|---|---|---|
61321466 | Apr 2010 | US |